PMHNP Scope of Practice for Narcolepsy in Georgia

If you’re a psychiatrist or PMHNP considering treating narcolepsy patients via telehealth, you’re probably asking: Can I legally prescribe stimulants and controlled substances remotely? What about Schedule II drugs like Adderall or methylphenidate? The short answer is yes, for now — but the rules are complicated, changing, and vary wildly by state.

Narcolepsy treatment often requires Schedule II stimulants (amphetamines, methylphenidate), Schedule IV wakefulness agents (modafinil, armodafinil), or Schedule III medications like sodium oxybate. Under normal federal law — the Ryan Haight Act — prescribing any controlled substance via telemedicine requires at least one in-person medical evaluation. But since 2020, the DEA has repeatedly extended COVID-era telehealth flexibilities that waive this requirement, most recently through December 31, 2026. That gives providers a stable window to prescribe narcolepsy medications remotely, but permanent rules are still pending.

Here’s what you need to know to stay compliant — and why some states make this easier than others.

Federal Law: The Ryan Haight Act and DEA Telehealth Extensions

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 amended the Controlled Substances Act to require an in-person medical evaluation before any controlled substance prescription via the internet or telemedicine (21 U.S.C. §829(e)). Narrow exceptions exist — VA patients, hospital-based care, covering for a provider who saw the patient in person — but they don’t cover most telemedicine scenarios.

When COVID hit in March 2020, the DEA waived the in-person exam requirement to prevent care disruptions. That waiver allowed providers to prescribe Schedule II–V medications via telehealth (video or phone) without ever meeting the patient in person, as long as the prescription was otherwise legitimate and all other CSA requirements were met (state licensure, DEA registration, etc.).

The federal Public Health Emergency ended in May 2023, which should have reinstated Ryan Haight restrictions. Instead, recognizing the chaos this would cause, the DEA issued multiple temporary extensions:

• Extension 1 (2023): Through November 2023
• Extension 2 (2024): Through December 31, 2024 (DEA, Nov 2024)
• Extension 3 (2026): Through December 31, 2026 (HHS Press Release, Jan 2, 2026)

Bottom line: As of early 2026, you can initiate and continue controlled substance prescriptions for narcolepsy via telehealth without an in-person visit — but only through the end of 2026. After that, permanent DEA rules will kick in, and they’ll likely impose some restrictions (initial supply limits, follow-up requirements, or carve-outs for specific conditions).

What Permanent Rules Are Coming?

The DEA proposed rules in early 2023 that would have required an in-person visit after an initial 30-day telemedicine prescription for Schedule II drugs, with some substances (like stimulants) potentially banned from telehealth initiation entirely. Public backlash was fierce — over 38,000 comments, Congressional pushback, patient advocacy groups (DEA, Oct 2023). The DEA pulled back, extended the flexibilities, and went back to the drawing board.

As of February 2026, the only finalized telemedicine-specific rules are niche: one expanding buprenorphine prescribing for opioid use disorder via telehealth, and one allowing continuity of care for VA patients (DEA, Jan 17, 2025). For narcolepsy, there’s no special exception yet — you’re operating under the blanket COVID-era extension.

Strategy: Expect new permanent rules sometime in 2025–2026. They’ll likely be more flexible than the original proposal (maybe allowing Schedule III–V or certain Schedule IIs with safeguards), but plan for some in-person requirement eventually. Start building hybrid care models now — partnerships with local sleep clinics for diagnostic testing, or arranging periodic in-person visits for established patients.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-Specific Telehealth Prescribing Rules: Where Narcolepsy Gets Tricky

Even with federal flexibilities in place, state laws add another layer of regulation. Most states defer to federal law for controlled substances, but a few impose extra restrictions that directly impact narcolepsy care.

Florida: The Big Exception

Florida explicitly bans prescribing Schedule II controlled substances via telehealth — except for treating a psychiatric disorder, inpatient/hospice care, or nursing home residents (Fla. Stat. §456.47).

The problem: Narcolepsy is not a psychiatric disorder — it’s a neurological sleep disorder. That means a Florida psychiatrist or PMHNP cannot prescribe Adderall, Ritalin, or other Schedule II stimulants for narcolepsy via telehealth alone, even under the federal DEA waiver.

Workarounds:

• Prescribe modafinil or armodafinil (Schedule IV) via telehealth — these aren’t banned
• Require at least one in-person visit to start stimulants, then manage follow-ups remotely
• Partner with a local clinic or sleep specialist for the initial prescription

Florida PMHNPs face an additional hurdle: they can only prescribe 7 days’ worth of Schedule II for any one acute illness episode unless they’re a certified ‘psychiatric nurse’ treating a mental health disorder (Fla. Stat. §464.012). Since narcolepsy isn’t a psychiatric diagnosis, the 7-day cap applies. In practice, Florida NPs managing narcolepsy patients will need a physician involved for ongoing stimulant prescriptions.

New York: Aligned with Federal Rules (For Now)

New York’s Department of Health finalized regulations in May 2025 requiring an in-person exam before prescribing controlled substances via telehealth — unless you comply with applicable federal law (Nixon Peabody, June 2025).

Translation: As long as the DEA waiver is in effect (through 2026), NY providers can prescribe narcolepsy meds via telehealth without meeting the patient in person. If/when the DEA reinstates the in-person requirement, New York’s rule will automatically enforce it too.

Key points:

• Psychiatrists in NY have full prescriptive authority — no restrictions beyond federal law
• PMHNPs with 3,600+ hours of experience can practice independently in NY (no collaborating physician needed) and prescribe Schedule II–V (Rivkin Radler, Apr 2022)
• Must check the I-STOP PDMP (prescription monitoring program) before every controlled substance prescription
• E-prescribing is mandatory for controlled substances

New York is one of the most NP-friendly states for telehealth narcolepsy care — experienced PMHNPs can diagnose, prescribe, and manage patients entirely independently.

Texas: Video Required, NPs Can’t Prescribe Schedule II Outpatient

Texas allows telehealth establishment of a patient relationship via live two-way video (phone-only doesn’t count for prescribing). The state bans telehealth prescribing of opioids for chronic pain, but narcolepsy isn’t chronic pain, so that doesn’t apply (CCHP, Fall 2025).

The catch: Texas does not allow APRNs or PAs to prescribe Schedule II controlled substances in outpatient settings — only in hospitals (with 24+ hour admission), emergency departments, or hospice care (Texas Medical Board FAQ). A supervising physician must write any outpatient Schedule II prescription.

What this means for narcolepsy care:

• Psychiatrists can prescribe stimulants via telehealth (video required), following federal rules
• PMHNPs can prescribe modafinil (Schedule IV) under a physician delegation agreement, but not Adderall or Ritalin — the physician must handle those
• Telehealth platforms operating in Texas need psychiatrists or MDs on staff to manage Schedule II prescriptions for narcolepsy patients

Texas also limits a supervising physician to 7 NPs/PAs in outpatient settings, which constrains scaling NP-heavy practices.

California: NPs Gaining Independence

California recently implemented AB 890, allowing NPs with 4,600+ hours of clinical experience (or 3 years under supervision) to practice independently — including prescribing Schedule II–V controlled substances (RxAgent, Dec 2025).

Requirements:

• Must complete specific pharmacology coursework on controlled substances (including addiction risk) before obtaining Schedule II furnishing privileges (CA Board of RN)
• Need a DEA registration and California furnishing number with Schedule II authority
• Must check the CURES PDMP before prescribing controlled substances (initial Rx and at least every 4 months thereafter)

Bottom line: Experienced California PMHNPs can now diagnose narcolepsy and prescribe stimulants independently — a major expansion of access. Newer NPs still need a supervising physician and standardized procedures until they qualify for full practice authority.

Pennsylvania: Collaboration Required, 30-Day Schedule II Limit for NPs

Pennsylvania is a restricted practice state. CRNPs (Certified Registered Nurse Practitioners) must have a collaborative agreement with a physician to prescribe (CCHP, Fall 2025).

Key limits:

• NPs can prescribe Schedule II–V if the collaborating physician approves it
• 30-day maximum supply of Schedule II for any one patient; beyond that, the physician must be consulted and the patient re-evaluated
• Schedule III–IV: 90-day supply limit

For narcolepsy, a PA PMHNP will likely involve the physician for periodic review, especially if high doses or long-acting stimulants are needed continuously. The state removed the old 72-hour initial limit, but the 30-day cap remains (PA Bulletin, 2021).

Telehealth: Pennsylvania allows telehealth prescribing under the collaborating physician’s oversight as long as DEA policy permits. No state-specific ban on remote controlled substance prescribing beyond federal requirements.

Illinois: Full Practice Authority with Conditions

Illinois allows NPs to attain Full Practice Authority (FPA) after 4,000 hours of clinical practice under collaboration + 250 hours of continuing education (RxAgent, Dec 2025). Once granted FPA, NPs can prescribe Schedule II–V independently.

Caveat: If an FPA-NP prescribes benzodiazepines or opioids, they must maintain a ‘consultation relationship’ with a physician. Stimulants (Schedule II but not opioids) are likely not subject to this requirement, meaning an Illinois FPA-NP can prescribe Adderall or methylphenidate independently.

Requirements:

• Apply for a Mid-Level Practitioner Controlled Substance License from the state (in addition to DEA registration)
• Check the Illinois PMP before prescribing
• E-prescribing mandatory for controlled substances as of January 2023

Illinois is another NP-friendly state for narcolepsy telehealth — experienced PMHNPs can handle diagnosis and treatment solo.

Psychiatrist vs PMHNP Scope: Who Can Do What?

Psychiatrists (MD/DO)

• Full prescriptive authority in all 50 states for any Schedule II–V medication within their competency
• No state-imposed restrictions on treating narcolepsy (it’s a medical diagnosis, not just psychiatric)
• Must have:
• State medical license in the patient’s state
• DEA registration for Schedule II–V
• Compliance with state PDMP checks, e-prescribing mandates
• Reality check: Narcolepsy is often managed by neurologists or sleep specialists, but there’s no law barring psychiatrists from treating it. You just need to be comfortable with the diagnosis (often requires coordination with a sleep lab for polysomnography and MSLT testing) and the medication management (stimulants, sodium oxybate REMS enrollment, etc.).

PMHNPs

• Scope varies wildly by state — from full independence (CA, NY, IL after meeting criteria) to no Schedule II authority at all (TX outpatient, GA)
• Key decision points:
• Can they practice independently? (Full practice states: CA, NY, IL after hours; Restricted: TX, FL, PA)
• Can they prescribe Schedule II outpatient? (No: TX, GA; Limited: FL 7-day cap unless psychiatric nurse; Yes with conditions: CA, NY, IL, PA 30-day)
• Do they need physician collaboration? (Yes: TX, FL, PA; No after experience: CA, NY, IL)

For narcolepsy specifically: PMHNPs are well-positioned because they already prescribe stimulants for ADHD (similar drugs, similar monitoring). The overlap between psychiatric and sleep disorder management (stimulants for wakefulness, antidepressants for cataplexy) makes this a natural fit — but you need to know your state’s scope rules.

Practical Considerations: Making Telehealth Narcolepsy Care Work

1. Diagnostic Confirmation

Narcolepsy diagnosis typically requires overnight polysomnography + Multiple Sleep Latency Test (MSLT), which must be done in-person at a sleep lab. As a telehealth provider, you’ll need to:

• Coordinate referrals to local sleep centers in the patient’s area
• Review sleep study results remotely
• Confirm diagnosis meets ICSD-3 criteria (Type 1 with cataplexy, Type 2 without)

This is one area where telehealth alone isn’t enough — you’re managing the medication side, but diagnostic testing requires brick-and-mortar infrastructure.

2. REMS Programs and Specialty Meds

Sodium oxybate (Xyrem, Xywav) is Schedule III with an FDA-mandated REMS program — you must be specially enrolled to prescribe it, and patients must go through a centralized pharmacy. Factor in the administrative overhead if you’re prescribing this.

3. PDMP Checks Are Non-Negotiable

Nearly every state requires checking the Prescription Drug Monitoring Program before prescribing controlled substances. Requirements vary:

• California: Check CURES before initial Rx and at least every 4 months
• New York: Check I-STOP before every controlled Rx
• Texas, FL, PA, IL: Similar mandates

Most telehealth platforms integrate PDMP access, but you need to document compliance in every patient chart.

4. E-Prescribing Mandates

Many states now require electronic prescribing for controlled substances (EPCS):

• Mandatory: CA, NY, IL (as of 2023), FL (with limited exceptions)
• Required technology: Two-factor authentication, identity proofing, DEA-compliant software

If you’re still using paper prescriptions, you’re out of compliance in most states.

5. Plan for DEA Rule Changes

When the DEA finalizes permanent telehealth rules (likely 2025–2026), you’ll probably need to:

• Conduct an initial in-person visit for new narcolepsy patients starting Schedule II meds, OR
• Limit initial telehealth prescriptions to 30 days until an in-person exam occurs

Start building relationships with local clinics or sleep specialists now so you have referral pathways when rules tighten.

State-by-State Quick Reference

Economics: Why Telehealth Platforms Make Sense for Narcolepsy Care

Let’s talk about patient acquisition costs, because that’s what determines whether you can actually build a sustainable narcolepsy practice.

DIY Marketing Reality Check:

• SEO: Takes 6–12 months of consistent investment before generating meaningful patient flow. Most solo providers don’t have the expertise or patience.
• Google Ads: Mental health keywords cost $15–40+ per click. Most clicks don’t convert. A realistic cost per booked patient is $200–400+.
• Directory Listings (Psychology Today, Zocdoc): Monthly subscription fees + you compete with hundreds of other providers on the same page. Zocdoc charges $35–100+ per booking, but total monthly cost including subscription adds up fast.
• All-in DIY cost: $3,000–5,000/month with uncertain results, months before ROI, and wasted ad spend on clicks that don’t convert.

Platform Model (e.g. Klarity Health):

• Pay-per-appointment — you pay a standard listing fee only when a qualified patient books with you
• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you see patients

The math: Instead of gambling $3,000–5,000/month on marketing with no guaranteed results, you pay only when a patient shows up. That’s guaranteed ROI vs high-risk DIY marketing.

For narcolepsy specifically — a rare condition (affects ~1 in 2,000 people) with patients often searching for specialists outside their local area — being visible on a national telehealth platform is the fastest path to patient volume. You’re not competing for the same local ADHD or depression patients every other psychiatrist is targeting with Google Ads. You’re reaching underserved narcolepsy patients who can’t find local specialists.

FAQ: Narcolepsy Telehealth Prescribing

Can I prescribe Schedule II stimulants for narcolepsy via telehealth?

Yes, through December 31, 2026 under the DEA’s COVID-era telehealth flexibilities (HHS, Jan 2, 2026). After that, permanent DEA rules will likely require some in-person component. Exception: Florida bans Schedule II telehealth prescribing for narcolepsy (not a psychiatric disorder), so you’ll need an in-person visit there (Fla. Stat. §456.47).

Do I need to see the patient in person for the initial visit?

Not under current federal rules (through 2026). But some states have their own requirements — Florida being the big exception for narcolepsy. Plan for this to change in 2027 when permanent DEA rules take effect.

Can PMHNPs treat narcolepsy independently?

Depends on the state. In New York, California (after 4,600 hours), and Illinois (after 4,000 hours), experienced PMHNPs can diagnose and prescribe independently. In Texas, Georgia, and Florida, PMHNPs face significant restrictions on Schedule II prescribing — Texas bans it outpatient entirely, Florida limits it to 7 days for non-psychiatric conditions.

What about sodium oxybate (Xyrem)?

Sodium oxybate is Schedule III with a REMS program — you must be specially enrolled with the manufacturer to prescribe it. It’s dispensed through a centralized pharmacy (not a local one), so telehealth prescribing is feasible, but the administrative burden is higher.

Do I have to check the PDMP every time?

Yes. Most states require PDMP checks before prescribing any controlled substance. Some (like California) allow quarterly checks for ongoing patients, but initial prescriptions always require a check. Non-compliance can result in state board discipline.

What happens if the DEA waiver expires in 2026?

You’ll likely need to either: (1) conduct an initial in-person exam before prescribing Schedule II meds, or (2) limit initial telehealth prescriptions to 30 days with a subsequent in-person visit required. The DEA is still finalizing permanent rules, so watch for updates in late 2025/early 2026.

Next Steps: Join a Platform Built for Provider Success

If you’re a psychiatrist or PMHNP looking to expand into narcolepsy care (or already treating it and want to scale), joining a telehealth platform removes the headache of patient acquisition, credentialing, and compliance.

Klarity Health’s model:

• Pre-qualified narcolepsy patients actively seeking care
• No upfront marketing costs — pay only when you see patients
• Full telehealth infrastructure (video, e-prescribing, EHR, PDMP integration)
• Multi-state licensing support to help you expand beyond your home state
• Both insurance and cash-pay options for patient flexibility

Instead of spending months building SEO, burning cash on Google Ads, or competing with hundreds of providers on Psychology Today, you get matched with patients who need your expertise and are ready to book.

Explore Klarity’s provider network and start seeing narcolepsy patients without the patient acquisition risk.

Citations and Sources

1. HHS Press Release (Jan 2, 2026) – ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (www.hhs.gov)

2. DEA Press Release (Nov 15, 2024) – ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’ (www.dea.gov)

3. 21 U.S.C. §829(e) – Ryan Haight Act (via Legal Information Institute, Cornell) – Defines in-person medical evaluation requirement for controlled substance prescribing via telemedicine (www.law.cornell.edu)

4. Nixon Peabody Legal Alert (June 18, 2025) – ‘New York State Finalizes Telemedicine Rule for Controlled Substances’ (www.nixonpeabody.com)

5. Florida Statutes §456.47 – Use of Telehealth to Provide Services (prohibits Schedule II teleprescribing except for psychiatric disorders, hospice, etc.) (www.leg.state.fl.us)

Source:

• https://www.law.cornell.edu/definitions/uscode.php?defid=21-USC-1796173870-113781527&height=800&iframe=true&termoccur=999&term_src=title%3A21%3Achapter%3A13%3Asubchapter%3AI%3Apart%3AC%3Asection%3A831&width=840#:~:text=,that%20a%20prescription%20has%20been
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=promulgate%20a%20final%20set%20of,Medications%2C%E2%80%9D%20was%20submitted%20to%20the
• https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care#:~:text=On%20January%2017%2C%202025%2C%20DEA,to%20as%20the%20%E2%80%9CTwo%20Final
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.tmb.state.tx.us/page/facility-based-prescriptive-delegation#:~:text=at%20the%20hospital%E2%80%99s%20facility,from%20a%20qualified%20hospice%20provider
• https://www.cchpca.org/resources/state-telehealth-laws-and-reimbursement-policies-report-fall-2025/#:~:text=Texas%20regulations%20emphasize%20continuity%20of,Note
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=match%20at%20L114%20The%20rule,and%20the%20US%20Department%20of
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=In%20short%2C%20the%20exception%20permits,as%20a%20condition%20of%20state
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Conversely%2C%20in%20Restricted%20Practice%20states,expand%20this%20scope%20%206